Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
复制标题
DOI：
10.1038/bjc.1989.377
复制
发表时间：
1989-12
影响因子：
8.8
通讯作者：
Nordling, S
中科院分区：
文献类型：
--
作者：
Haglund, C;Lindgren, J;Roberts, P J;Kuusela, P;Nordling, S
用免疫过氧化物酶染色法研究了一种新的肿瘤相关抗原CA 242（由单克隆抗体C 242定义）在正常胰腺、胰腺炎和良性及恶性胰腺肿瘤的福尔马林固定、石蜡包埋组织切片中的表达。C 242抗体的抗原决定簇是一种唾液酸化的碳水化合物结构，与肿瘤标志物抗原CA 19-9和CA 50相关，但化学性质不同。41例（93%）良好至中度分化的胰腺导管腺癌和所有囊腺癌中有38例CA 242阳性。染色在细胞的顶端边缘和管腔内粘液中最强烈。7例低分化腺癌中仅2例染色，阳性细胞数少于高分化癌。只有偶尔的细胞染色的五个未分化癌之一。91%（21/23）的慢性胰腺炎标本中部分大导管呈阳性。在急性胰腺炎小终末导管，中央腺泡细胞和一些大导管CA 242染色。在正常胰腺中，只有少数终末小管呈CA 242阳性.癌组织中CA 242的染色强度总是高于癌旁正常胰腺组织. CA 242的结果与肿瘤标志物抗原CA 50和CA 19-9的结果进行了比较。用荧光免疫分析法测定23例胰腺癌患者血清CA 242水平。15例（65%）患者的数值升高。血清水平和CA 242抗原的免疫组化表达之间没有明确的相关性。CA 242在胰腺组织中的表达类似于CA 50的表达，并且类似于CA 19-9。该抗原在许多胰腺癌患者的血清中表达，因此是血清肿瘤标志物的潜在候选者。
The expression of a novel tumour associated antigen CA 242, defined by the monoclonal antibody C 242, was studied by immunoperoxidase staining in formalin-fixed, paraffin-embedded tissue sections from normal pancreata, pancreata with pancreatitis and benign and malignant pancreatic neoplasms. The antigenic determinant of the C 242 antibody is a sialylated carbohydrate structure, related but chemically different from tumour marker antigens CA 19-9 and CA 50. Thirty-eight of 41 (93%) well to moderately differentiated ductal adenocarcinomas of the pancreas and all cystadenocarcinomas were positive for CA 242. The staining was most intense in the apical border of the cells, and in the intraluminal mucus. Only two out of seven poorly differentiated adenocarcinomas stained, and the number of positive cells was smaller than in well differentiated carcinomas. Only occasional cells were stained in one out of five anaplastic carcinomas. Part of large ducts were positive in 91% (21/23) specimens of chronic pancreatitis. In acute pancreatitis small terminal ducts, centro-acinar cells and some large ducts stained for CA 242. In normal pancreas only a few small terminal ducts were CA 242 positive. Carcinomas always stained more strongly for CA 242 than normal pancreatic tissue adjacent to the carcinoma. The results of CA 242 are compared with those of tumour marker antigens CA 50 and CA 19-9. Serum CA 242 levels were determined in 23 of the patients with pancreatic cancer using a fluoroimmunoassay. Fifteen (65%) patients had an elevated value. There was no clear-cut correlation between the serum levels and the immunohistochemical expression of the CA 242 antigen. The expression of CA 242 in pancreatic tissue resembles that of CA 50 and is similar to CA 19-9. The antigen is expressed in serum of many patients with pancreatic cancer and, therefore, is a potential candidate for a serum tumour marker.